X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SANOFI INDIA ALKEM LABORATORIES/
SANOFI INDIA
 
P/E (TTM) x - 39.5 - View Chart
P/BV x 6.9 8.5 81.5% View Chart
Dividend Yield % 0.6 1.1 59.0%  

Financials

 ALKEM LABORATORIES   SANOFI INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SANOFI INDIA
Dec-16
ALKEM LABORATORIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,5894,560 34.8%   
Low Rs1,2324,400 28.0%   
Sales per share (Unadj.) Rs417.51,028.5 40.6%  
Earnings per share (Unadj.) Rs56.3129.0 43.7%  
Cash flow per share (Unadj.) Rs64.7186.0 34.8%  
Dividends per share (Unadj.) Rs12.7068.00 18.7%  
Dividend yield (eoy) %0.91.5 59.3%  
Book value per share (Unadj.) Rs292.9753.6 38.9%  
Shares outstanding (eoy) m119.5723.03 519.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 77.6%   
Avg P/E ratio x25.134.7 72.1%  
P/CF ratio (eoy) x21.824.1 90.5%  
Price / Book Value ratio x4.85.9 81.0%  
Dividend payout %22.652.7 42.8%   
Avg Mkt Cap Rs m168,653103,174 163.5%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m9,1713,592 255.3%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m49,91523,686 210.7%  
Other income Rs m1,645708 232.4%   
Total revenues Rs m51,56124,394 211.4%   
Gross profit Rs m8,4825,281 160.6%  
Depreciation Rs m1,0061,313 76.6%   
Interest Rs m67115 4,470.7%   
Profit before tax Rs m8,4514,661 181.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,691 95.0%   
Profit after tax Rs m6,7312,970 226.6%  
Gross profit margin %17.022.3 76.2%  
Effective tax rate %19.036.3 52.4%   
Net profit margin %13.512.5 107.5%  
BALANCE SHEET DATA
Current assets Rs m27,06215,673 172.7%   
Current liabilities Rs m15,3246,678 229.5%   
Net working cap to sales %23.538.0 61.9%  
Current ratio x1.82.3 75.2%  
Inventory Days Days6776 87.5%  
Debtors Days Days4122 185.0%  
Net fixed assets Rs m12,6108,098 155.7%   
Share capital Rs m239230 103.8%   
"Free" reserves Rs m34,49017,088 201.8%   
Net worth Rs m35,02717,356 201.8%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38725,400 214.1%  
Interest coverage x13.6311.7 4.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 98.4%   
Return on assets %13.611.8 115.8%  
Return on equity %19.217.1 112.3%  
Return on capital %24.926.9 92.3%  
Exports to sales %12.924.5 52.9%   
Imports to sales %3.128.0 11.0%   
Exports (fob) Rs m6,4615,801 111.4%   
Imports (cif) Rs m1,5406,627 23.2%   
Fx inflow Rs m6,5637,145 91.9%   
Fx outflow Rs m3,0126,846 44.0%   
Net fx Rs m3,552299 1,187.8%   
CASH FLOW
From Operations Rs m7,2593,226 225.0%  
From Investments Rs m1,864-1,555 -119.9%  
From Financial Activity Rs m-9,273-1,818 510.0%  
Net Cashflow Rs m-150-147 102.0%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 33.1 14.4 229.9%  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 15,184 450.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS